IAs bispecific antibodies, fusion proteins, and ADCs become more structurally diverse, drug developers face increasing pressure to deliver reliable, regulatory-ready data. No single platform can meet these demands alone.

Svar Life Science and Lablytica Life Science are leading a shift toward integration—combining ligand-binding assay expertise with LC-MS/MS specialization to offer smarter, molecule-driven strategies from discovery to clinic.

Traditional workflows often force-fit technologies, leading to bottlenecks and costly rework. This collaboration builds workflows around the molecule—not the method.

Download the full editorial article to explore how this partnership is reshaping bioanalysis.